Business Wire

MEDI-GLOBE-GROUP

29.4.2022 18:30:04 CEST | Business Wire | Press release

Share
Groundbreaking research cooperation: The Medi-Globe Group and the IHU in Strasbourg are developing the world's first AI software for detecting pancreatic diseases

The Medi-Globe Group has entered into a groundbreaking research cooperation with the French Institut Hospitalo-Universitaire (IHU) in Strasbourg. The goal of the collaboration is the world's first AI software for detecting diseases of the pancreas in endoscopic ultrasound examinations. As industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220429005471/en/

Medi-Globe Group CEO Martin Lehner: "Together with the researchers at the IHU, we will develop the world's first software for the diagnosis of diseases of the pancreas to market maturity. The key technology here is artificial intelligence.”

“We are delighted to announce this special partnership with Medi-Globe Group. This collaboration is an important step in realizing our goal of being a technology leader in the application of artificial intelligence in the field of early detection of pancreatic diseases. Our vision has been to provide technologies that help physicians achieve the best outcome for their patients,” explains Benoit Gallix, CEO of IHU Strasbourg.

Important milestone in the diagnosis of pancreatic cancer in sight

Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose for physicians. Early detection is crucial for the patient's chance of survival. Today in Europe more than 90 percent of patients with pancreatic cancer die.

"In the future, with the support of artificial intelligence, we will be able to make the experience of the world's leading gastroenterologists available to all physicians. Our successful cooperation with the IHU has the potential to revolutionize the diagnosis of pancreatic diseases", says Marc Jablonowski, Chief Technology & Innovation Officer (CTIO) of the Medi-Globe Group.

About Medi-Globe Group

The Medi-Globe Group is an innovative, fast-growing and internationally oriented medical technology group in the fields of urology, gastroenterology and pneumology. The head office is in Achenmuehle in Bavaria. Around 670 employees work for the Medi-Globe Group in Germany, France, the Czech Republic, China, Brazil, the Netherlands and Austria. Customers include university clinics, specialist clinics, special medical facilities and specialists in gastroenterology, urology and pneumology in around 120 countries worldwide. The managing directors are Martin Lehner (CEO), Christian Klein (COO), Dr. Nikolaus König (CFO) and Marc Jablonowski (CTIO).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release

The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight

Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release

Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices

Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release

Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot

Freedom Holding Corp. Works With Ant International’s Antom to Simplify Online Shopping From China for Kazakhstan Consumers23.7.2026 07:30:00 CEST | Press release

Freedom Bank SuperApp to be promoted as a payment option on China’s leading e-commerce platforms through Antom On July 16, 2026, during a meeting between Timur Turlov, CEO of Freedom Holding Corp., and representatives of the global fintech market, the bank signed Memoranda of Understanding with Antom, a leading merchant payment and digitisation services provider under Ant International. The primary goal of this partnership is to develop innovative solutions to facilitate cross-border payments for consumers in Kazakhstan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722367119/en/ From left to right: Timur Turlov, CEO of Freedom Holding Corp., Leiming Chen, Senior Vice President and Chief Sustainability Officer of Ant International Antom will promote Freedom Bank SuperApp as a supported payment option on China’s leading e-commerce platforms. This move aims to create a seamless cross-border online shopping experience, allo

Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year23.7.2026 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 billion USD, surpassing 3 billion USD for the first time in the first six months of the year and representing net sales growth of 24.6% at constant currency1. Broad-based, double-digit growth in both International markets and the U.S. as well as in all product categories, primarily driven by volume and complemented by favorable mix. Outperforming the market in each product category, with net sales growth year-on-year at constant currency of 12.1% in Injectable Aesthetics, 16.4% in Dermatological Skincare, and 67.9% in Therapeutic Dermatology. Demonstrating leadership in dermatology through ongoing geographic expansion and differentiated innovation, including Nemluvio® (nemolizumab), which generated 433 million USD in net sales, Relfydess™ (RelabotulinumtoxinA), which continues to ra

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye